Guangzhou Innogen Pharmaceutical Group Co (HKSE:02591) Research & Development: HK$226.2 Mil (TTM As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HKSE:02591 Guangzhou Innogen Pharmaceutical Group Co Ltd HKSE:02591
9 GF Score
Price HK$7.60
! 2 Warning Signs
View Full Analysis

What is Guangzhou Innogen Pharmaceutical Group Co Research & Development?

Guangzhou Innogen Pharmaceutical Group Co HKSE:02591 +5.26% 9 Research & Development is HK$226.2 Mil as of Dec. 2025. GuruFocus rates HKSE:02591 with a GF Score™ of 9/100. The stock has 2 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Guangzhou Innogen Pharmaceutical Group Co's Research & Development for the six months ended in Dec. 2025 was HK$117.9 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 was HK$226.2 Mil.

Guangzhou Innogen Pharmaceutical Group Co  (HKSE:02591) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Guangzhou Innogen Pharmaceutical Group Co Research & Development Related Terms

Guangzhou Innogen Pharmaceutical Group Co Research & Development Historical Data

* Premium members only.

The historical data trend for Guangzhou Innogen Pharmaceutical Group Co's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Guangzhou Innogen Pharmaceutical Group Co Research & Development Chart

Guangzhou Innogen Pharmaceutical Group Co Annual Data
Trend Dec23 Dec24 Dec25
Research & Development
538.26 109.45 227.33

Guangzhou Innogen Pharmaceutical Group Co Semi-Annual Data
Dec23 Jun24 Dec24 Jun25 Dec25
Research & Development 0.00 55.88 54.03 108.30 117.87
HKSE:02591
9GF Score
Guangzhou Innogen Pharmaceutical Group Co Ltd HKSE:02591
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Guangzhou Innogen Pharmaceutical Group Co Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$226.2 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of HK$226.2 Mil mean?
Guangzhou Innogen Pharmaceutical Group Co (HKSE:02591) has a Research & Development of HK$226.2 Mil as of Dec. 2025. Research and development expense is the total cost for research and development activities. View historical data on Guangzhou Innogen Pharmaceutical Group Co and its competitors.
Is Guangzhou Innogen Pharmaceutical Group Co's Research & Development too high?
Guangzhou Innogen Pharmaceutical Group Co's current Research & Development is HK$226.2 Mil. Overall, Guangzhou Innogen Pharmaceutical Group Co has a GF Score™ of 9/100, reflecting its overall financial health beyond just this single metric.
How does Guangzhou Innogen Pharmaceutical Group Co's Research & Development compare to VRTX and REGN?
Guangzhou Innogen Pharmaceutical Group Co's Research & Development of HK$226.2 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Biotechnology company?
A good Research & Development depends on the Biotechnology industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Guangzhou Innogen Pharmaceutical Group Co and its competitors. Guangzhou Innogen Pharmaceutical Group Co's current Research & Development is HK$226.2 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Guangzhou Innogen Pharmaceutical Group Co stock overvalued right now?
Guangzhou Innogen Pharmaceutical Group Co (HKSE:02591) has a current Research & Development of HK$226.2 Mil. The current Research & Development is HK$226.2 Mil. Guangzhou Innogen Pharmaceutical Group Co's overall GF Score™ is 9/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Guangzhou Innogen Pharmaceutical Group Co (HKSE:02591), the current Research & Development is HK$226.2 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Guangzhou Innogen Pharmaceutical Group Co Business Description

Address No. 2 Tengfei Second Street, Room 409, Building H Self-numbered Creative Building, China-Singapore Guangzhou Knowledge City, Huangpu District, Guangdong Province, Guangzhou, CHN
Guangzhou Innogen Pharmaceutical Group Co Ltd is a company in Asia to commercialize, a humanized, long-acting glucagon-like peptide-1 (GLP-1) receptor agonist. It has commercialized Efsubaglutide Alfa (brand name: Diabegone), its Core Product, for the treatment of type 2 diabetes (T2D) in China. Its core business model is to discover, develop and commercialize therapies for diabetes and other metabolic diseases. The company has built a pipeline of drug candidates namely YN014, YN401, YN209, YN202,YN203 targeting diabetes and other metabolic diseases.
9GF Score

Get the complete analysis for HKSE:02591

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$7.60
Price